149 related articles for article (PubMed ID: 30071628)
1. Botulinum Neurotoxin F Subtypes Cleaving the VAMP-2 Q
Sikorra S; Skiba M; Dorner MB; Weisemann J; Weil M; Valdezate S; Davletov B; Rummel A; Dorner BG; Binz T
Toxins (Basel); 2018 Aug; 10(8):. PubMed ID: 30071628
[TBL] [Abstract][Full Text] [Related]
2. Comparative characterization of botulinum neurotoxin subtypes F1 and F7 featuring differential substrate recognition and cleavage mechanisms.
Guo J; Chan EW; Chen S
Toxicon; 2016 Mar; 111():77-85. PubMed ID: 26748154
[TBL] [Abstract][Full Text] [Related]
3. Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins.
Sikorra S; Henke T; Galli T; Binz T
J Biol Chem; 2008 Jul; 283(30):21145-52. PubMed ID: 18511418
[TBL] [Abstract][Full Text] [Related]
4. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
Schmidt JJ; Stafford RG
Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5.
Kalb SR; Baudys J; Webb RP; Wright P; Smith TJ; Smith LA; Fernández R; Raphael BH; Maslanka SE; Pirkle JL; Barr JR
FEBS Lett; 2012 Jan; 586(2):109-15. PubMed ID: 22172278
[TBL] [Abstract][Full Text] [Related]
6. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
7. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
Lam KH; Sikorra S; Weisemann J; Maatsch H; Perry K; Rummel A; Binz T; Jin R
Pathog Dis; 2018 Jun; 76(4):. PubMed ID: 29688327
[TBL] [Abstract][Full Text] [Related]
8. Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin.
Chen S; Hall C; Barbieri JT
J Biol Chem; 2008 Jul; 283(30):21153-9. PubMed ID: 18511417
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of substrate recognition by the novel Botulinum Neurotoxin subtype F5.
Guo J; Chan EW; Chen S
Sci Rep; 2016 Jan; 6():19875. PubMed ID: 26794648
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A).
Kalb SR; Baudys J; Raphael BH; Dykes JK; Lúquez C; Maslanka SE; Barr JR
Anal Chem; 2015 Apr; 87(7):3911-7. PubMed ID: 25731972
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of a novel botulinum neurotoxin.
Zhang S; Masuyer G; Zhang J; Shen Y; Lundin D; Henriksson L; Miyashita SI; Martínez-Carranza M; Dong M; Stenmark P
Nat Commun; 2017 Aug; 8():14130. PubMed ID: 28770820
[TBL] [Abstract][Full Text] [Related]
12. Expression and biochemical characterization of light chains of Botulinum neurotoxin subtypes F5 and F7.
Guo J; Chen S
Protein Expr Purif; 2015 Jul; 111():87-90. PubMed ID: 25858313
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of substrate recognition and specificity of botulinum neurotoxin serotype F.
Chen S; Wan HY
Biochem J; 2011 Jan; 433(2):277-84. PubMed ID: 21029044
[TBL] [Abstract][Full Text] [Related]
14. Different substrate recognition requirements for cleavage of synaptobrevin-2 by Clostridium baratii and Clostridium botulinum type F neurotoxins.
Kalb SR; Baudys J; Egan C; Smith TJ; Smith LA; Pirkle JL; Barr JR
Appl Environ Microbiol; 2011 Feb; 77(4):1301-8. PubMed ID: 21169446
[TBL] [Abstract][Full Text] [Related]
15. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F.
Agarwal R; Schmidt JJ; Stafford RG; Swaminathan S
Nat Struct Mol Biol; 2009 Jul; 16(7):789-94. PubMed ID: 19543288
[TBL] [Abstract][Full Text] [Related]
16. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.
Hanson MA; Stevens RC
Nat Struct Biol; 2000 Aug; 7(8):687-92. PubMed ID: 10932255
[TBL] [Abstract][Full Text] [Related]
17. New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency.
Burgin D; Périer C; Hackett G; Elliott M; Kwan D; Hornby F; Mir I; Maignel J; Liu SM; Beard M
Toxins (Basel); 2021 Nov; 13(12):. PubMed ID: 34941672
[TBL] [Abstract][Full Text] [Related]
18. Purification and Characterization of Recombinant Botulinum Neurotoxin Serotype FA, Also Known as Serotype H.
Hackett G; Moore K; Burgin D; Hornby F; Gray B; Elliott M; Mir I; Beard M
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29751611
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the functional activity of botulinum neurotoxin subtype B6.
Kohda T; Nakamura K; Hosomi K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.
Wang D; Krilich J; Pellett S; Baudys J; Tepp WH; Barr JR; Johnson EA; Kalb SR
Biochim Biophys Acta; 2013 Dec; 1834(12):2722-8. PubMed ID: 24096023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
